Health & Fitness
Health and Fitness
Health and Fitness
Wed, October 20, 2010
Tue, October 19, 2010
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2010 Financial Results on November 1, 2010
BOTHELL, Wash.--([ BUSINESS WIRE ])--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2010 financial results on Monday, November 1, 2010, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Monday, November 1, 2010
2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET)
- Telephone (877) 941-8632 (domestic) or (480) 629-9820 (international); conference ID 4373835
- Webcast available at [ http://www.seattlegenetics.com ] in the Investors and News section
REPLAY access
- Telephone replay will be available beginning at approximately 4:00 p.m. PT on November 1, 2010 through 4:00 p.m. PT on November 3, 2010 by calling (800) 406-7325 (domestic) or (303) 590-3030 (international); conference ID 4373835
- Webcast replay will be available on the Seattle Genetics website at [ http://www.seattlegenetics.com ] in the Investors and News section
About Seattle Genetics
Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company recently reported positive top-line data from both a pivotal Hodgkin lymphoma trial and phase II anaplastic large cell lymphoma trial with its lead product candidate, brentuximab vedotin, and plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first half of 2011. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at [ www.seattlegenetics.com ].
